Teva Pharmaceuticals won a major reprieve Monday when a Massachusetts federal judge delayed an impending False Claims Act trial threatening $10 billion in liability and permitted the drugmaker to pursue First Circuit review of a hotly contested FCA issue that has opened a clear circuit split.
Former President Donald Trump should face trial in January on charges of trying to nullify his defeat in the 2020 presidential election, special counsel Jack Smith said Thursday, arguing that the accelerated timeline in the historic case would "vindicate the public's strong interest in a speedy trial."
Amid revelations of lucrative links between captains of industry and some U.S. Supreme Court members, Justice Elena Kagan countenanced the idea of Congress imposing ethics rules and said the justices might do so themselves, a conciliatory contrast with combative words recently from Justice Samuel Alito.
The nation's health policy engine has a full head of steam in the second half of 2023, fueled by regulators asserting legally questionable powers over the booming diagnostics industry, a divided Congress chasing compromise on drug prices and a scramble by federal officials to manage the promise and peril of artificial intelligence in health care.
The U.S. Department of Justice will put Teva Pharmaceuticals in grave danger by pursuing more than $10 billion at an impending False Claims Act trial, amplifying the need for immediate First Circuit review of a question on kickbacks that has cleaved other appellate courts, the drugmaker said Wednesday.